COMMUNIQUÉS West-GlobeNewswire
-
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
09/07/2026 -
Censozo Announces Online Educational Resources Focused on Wellness, Recovery Support, and Personal Growth
09/07/2026 -
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09/07/2026 -
ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
09/07/2026 -
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026 -
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026 -
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
09/07/2026 -
Applied Biologics Introduces ECM Preservation Technology™ as the Proprietary Manufacturing Platform Behind XWRAP®
09/07/2026 -
Xealth Launches Support for Health Systems’ CMS ACCESS Participation, Targeting Up to 5% MSSP ACO Savings
09/07/2026 -
TOMI Reports 124% Increase in Preliminary Second Quarter Revenue; Preliminary Six Months Revenue Combined with Open Orders Surpass Full Year 2025 Revenue
09/07/2026 -
The Lenny Peters Foundation and 20 Years of Transforming Lives and Communities
09/07/2026 -
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 44th Annual Meeting July 15 - 18
09/07/2026 -
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026 -
Amplia Announces Publication of New FAK Inhibitor Patent Application
09/07/2026 -
Cynet Releases 2026 Global AI Security Readiness Report
09/07/2026 -
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026 -
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07/2026 -
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026 -
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026
Pages